<DOC>
	<DOCNO>NCT01863810</DOCNO>
	<brief_summary>Diabetic neuropathy known common complication diabetes , although estimate prevalence highly variable , range 1.6 90 % . Also , chronic pain accompany sleep disorder , depression , anxiety , thereby impair quality life increase societal cost . Pregabalin one proven market oral medicine manage chronic neuropathic pain diabetic patient . This study design randomize control trial demonstrate efficacy KW21052 pain reduction measure weekly mean pain score numerical pain rating scale ( NRS ) 8th week intervention inferior Lyrica .</brief_summary>
	<brief_title>Efficacy Safety KW21052 Compared Lyrica Diabetic Patients With Neuropathic Pain</brief_title>
	<detailed_description>Patient Reported Outcomes ( PRO ) use validated questionnaire patient diary assess efficacy analysis .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Type 1 2 diabetic patient Patients diagnose diabetic , distal , symmetrical , sensorimotor polyneuropathy 40mm VAS 4 NRS Informed consent patient Participating another clinical trial Pregnancy lactate Sensitivity pregabalin Significant underlying disease disorder Prohibited concomitant medication Significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Diabetic Neuropathy</keyword>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Pregabalin</keyword>
</DOC>